Robert J Mentz

North Carolina Clinical Research, Raleigh, North Carolina, United States

Are you Robert J Mentz?

Claim your profile

Publications (106)681.85 Total impact

  • Jonathan Buggey · Robert J. Mentz · Anthony N. Galanos
    Heart Failure Clinics 08/2015; DOI:10.1016/j.hfc.2015.07.001 · 1.41 Impact Factor
  • Heart Failure Clinics 08/2015; DOI:10.1016/j.hfc.2015.07.003 · 1.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acute heart failure (AHF) is a complex syndrome with presentations ranging from hypotensive cardiogenic shock to hypertensive emergency with pulmonary edema. Most patients with AHF present with worsening of chronic HF signs and symptoms over days to weeks, and significant heterogeneity exists. It can, therefore, be challenging to characterize the overall population. The complexity of defining the AHF phenotype has been cited as a contributing cause for neutral results in most pharmacologic trials in patients with AHF. Dyspnea has been a routine inclusion criterion for AHF for over a decade, but the utility of current instruments for dyspnea assessment has been called into question. Furthermore, the threshold of clinical severity that prompts patient admission of an HF clinic visit may vary substantially across regions in global trials. Therefore, the inclusion of cardiac-specific biomarkers has been incorporated into AHF trials as 1 strategy to support inclusion of the target patient population and potentially enrich the population with patients at risk for clinical outcomes. In conclusion, we discuss strategies to support appropriate patient selection in AHF trials with an emphasis on using biomarker criteria that may improve the likelihood of success with future AHF clinical trials. Copyright © 2015 Elsevier Inc. All rights reserved.
    The American journal of cardiology 07/2015; DOI:10.1016/j.amjcard.2015.07.049 · 3.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We aimed to characterize the independent predictors of LVT following STEMI and the association with outcomes. The clinical predictors of left ventricular thrombus (LVT) formation after ST-segment elevation myocardial infarction (STEMI) are not well-defined in the contemporary era. We performed a retrospective analysis of STEMI patients at Duke from 2000 to 2011 who had a transthoracic echocardiogram within 90 days post-STEMI and compared patients with and without LVT (LVT+ vs. LVT-). Univariate Cox proportional hazards regression models of baseline characteristics were examined and significant variables were used in a multivariable model to assess adjusted relationships with LVT. A multivariable Cox PH survival model with covariate adjustments was used for assessment of LVT and long-term mortality. Of all eligible patients, 1734 patients met inclusion criteria and 4.3 % (N = 74) had a LVT. LVT+ patients tended to have a history of heart failure (HF) and higher initial troponin compared to LVT- patients. After adjustment, higher heart rate, non-white race, HF severity, and presence of left anterior descending artery (LAD) disease were independent predictors of LVT. There was a trend toward an association between LVT and increased all-cause mortality (HR 1.36; 95 % CI 0.84-2.21, P = 0.22), however this was not statistically significant. LVT was seen in over 4 % of this contemporary post-STEMI population. Several baseline characteristics were independently associated with LVT: Heart rate, HF severity, LAD disease, and non-white race. Prospective studies are warranted to determine whether anticoagulation in patients at increased risk for LVT improves outcomes.
    Journal of Thrombosis and Thrombolysis 07/2015; DOI:10.1007/s11239-015-1252-0 · 2.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Heart failure (HF) is an increasingly common syndrome associated with high mortality and economic burden, and there has been a paucity of new pharmacotherapies that improve outcomes over the past decade. However, recent data from a large, randomized controlled trial compared the novel agent LCZ696, a dual acting angiotensin receptor blocker and neprilysin inhibitor (ARNi), to the well-established angiotensin-converting enzyme (ACE) inhibitor enalapril and found significant reduction in mortality among the chronic, reduced ejection fraction HF population. Preclinical and clinical data suggest that neprilysin inhibition provides beneficial outcomes in HF patients by preventing the degradation of natriuretic peptides thereby promoting natriuresis, vasodilatation, and counteracting the negative cardiorenal effects of the up-regulated renin-angiotensin-aldosterone system. Agents such as omapatrilat combined neprilysin and ACE inhibition but had increased rates of angioedema. Goals of an improved safety profile provided the rationale for the development of the ARNi LCZ696. Along with significant reductions in mortality and hospitalizations, clinical trials suggest LCZ696 may improve surrogate markers of HF severity. In this paper, we review the preclinical and clinical data that has led to the development of LCZ696 and the understanding of the underlying mechanistic action and the robust clinical impact that LCZ696 may have in the near future. Copyright © 2015 Elsevier Inc. All rights reserved.
    Journal of cardiac failure 07/2015; DOI:10.1016/j.cardfail.2015.07.008 · 3.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Congestion is the most common reason for admissions and readmissions for heart failure (HF). The vast majority of hospitalized HF patients appear to respond readily to loop diuretics, but available data suggest that a significant proportion are being discharged with persistent evidence of congestion. Although novel therapies targeting congestion should continue to be developed, currently available agents may be utilized more optimally to facilitate complete decongestion. The combination of loop diuretics, natriuretic doses of mineralocorticoid receptor antagonists and vasopressin antagonists represents a regimen of currently available therapies that affects early and persistent decongestion, while limiting the associated risks of electrolyte disturbances, hemodynamic fluctuations, renal dysfunction and mortality.
    Expert Review of Cardiovascular Therapy 07/2015; 13(7):799-809. DOI:10.1586/14779072.2015.1053872
  • Robert J Mentz · Michel G Khouri
    [Show abstract] [Hide abstract]
    ABSTRACT: Heart failure with preserved ejection fraction (HFpEF) represents approximately 50% of the overall heart failure (HF) population(1), yet relatively few prognostic markers are used in routine clinical practice. Clinicians commonly assess symptom severity, prior HF hospitalizations, natriuretic peptide levels and comorbidity burden to characterize disease trajectory. Furthermore, without disease-modifying agents, the management of HFpEF is largely limited to optimization of volume status and comorbid conditions(2). In contrast, for patients with HF with reduced EF (HFrEF), clinicians incorporate an array of data from clinical evaluation and diagnostic testing to risk-stratify patients, individualize guideline-based medication regimens and determine optimal timing for implantable devices and advanced therapies. For instance, thresholds for echocardiographic and exercise testing parameters (e.g., EF and maximal oxygen consumption) are central components of the decision-making process for defibrillator implantation and advanced therapies such as ventricular assist devices(2). An equivalent prognostic marker to EF has not been identified for HFpEF patients despite the similarly high event rate compared to HFrEF cohorts(3, 4).
    Circulation 06/2015; DOI:10.1161/CIRCULATIONAHA.115.017683 · 14.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Worsening heart failure (WHF) symptoms despite initial therapy during admission for acute heart failure (AHF) is associated with worse outcomes. The association between the time of the WHF event and the intensity of WHF therapy with outcomes is unknown. In the PROTECT trial of 2033 AHF patients, we investigated the association between time of occurrence of WHF and intensity of therapy, with subsequent outcomes. WHF was defined by standardized, physician-determined assessment. Early WHF was defined as occurring on days 2-3 and late on days 4-7. Low intensity included restarting/increasing diuretics or vasodilators and high intensity included initiation of inotropes, vasopressors, inodilators, or mechanical support. Outcomes were death or cardiovascular/renal hospitalization over 60 days and death over 180 days. Of the 1879 patients with complete follow-up after day 7, 12.7% (n = 238) experienced WHF: 47.9% early and 52.1% late. Treatment intensity was low in 72.3% and high in 24.8% (2.9% missing). After adjusting for baseline predictors of outcome, WHF was associated with a trend toward increased 60-day death or cardiovascular/renal hospitalization [hazard ratio (HR) 1.26; 95% confidence interval (CI) 0.99-1.60; P = 0.063] and increased 180-day death (HR 1.77; 95% CI 1.33-2.34; P < 0.001). There was no evidence of a differential association between the time of occurrence of WHF and outcomes. High-intensity therapy was not significantly associated with increased event rates (180-day mortality: HR 1.44; 95% CI 0.80-2.59 vs. low). Inhospital WHF was associated with increased 180-day death. The time of occurrence and intensity of WHF therapy may provide less prognostic information than whether or not WHF occurred. © 2015 The Authors European Journal of Heart Failure © 2015 European Society of Cardiology.
    European Journal of Heart Failure 06/2015; 17. DOI:10.1002/ejhf.308 · 6.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: -Congestion is the most frequent cause for hospitalization in acute decompensated heart failure (ADHF). Although decongestion is a major goal of acute therapy, it is unclear how the clinical components of congestion (e.g., peripheral edema, orthopnea) contribute to outcomes after discharge or how well decongestion is maintained. -A post-hoc analysis was performed of 496 patients enrolled in the DOSE-AHF and CARRESS-HF trials during hospitalization with ADHF and clinical congestion. A simple "orthodema" congestion score was generated based on symptoms of orthopnea (≥2 pillows=2 points, <2 pillows=0 points) and peripheral edema (trace=0 points, moderate=1 point, severe=2 points) at baseline, discharge, and 60-day follow-up. Orthodema scores were classified as absent (score of 0), low-grade (score of 1-2), and high-grade (score of 3-4), and the association with death, rehospitalization or unscheduled medical visits through 60 days was assessed. At baseline, 65% of patients had high-grade orthodema and 35% had low-grade orthodema. At discharge, 52% patients were free from orthodema at discharge (score = 0) and these patients had lower 60-day rates of death, rehospitalization, or unscheduled visits (50%) compared to those with low-grade or high-grade orthodema (52% and 68%, respectively, p=0.038). Of the patients without orthodema at discharge, 27% relapsed to low-grade orthodema and 38% to high-grade orthodema at 60-day follow-up. -Increased severity of congestion by a simple orthodema assessment is associated with increased morbidity and mortality. Despite intent to relieve congestion, current therapy often fails to relieve orthodema during hospitalization or to prevent recurrence after discharge. Clinical Trial Registration-URL: Unique identifiers: NCT00608491, NCT00577135.
    Circulation Heart Failure 06/2015; DOI:10.1161/CIRCHEARTFAILURE.114.001957 · 5.95 Impact Factor
  • Anuradha Lala · Robert J Mentz
    Journal of the American College of Cardiology 06/2015; 65(21):2348-51. DOI:10.1016/j.jacc.2015.04.016 · 15.34 Impact Factor
  • Robert J Mentz
    Journal of Cardiovascular Medicine 06/2015; 16(6):401-3. DOI:10.2459/JCM.0000000000000194 · 1.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Furosemide has historically been the primary loop diuretic in heart failure patients despite data suggesting potential advantages with torsemide. We used the Duke Echocardiography Lab Database to investigate patients admitted with heart failure to Duke Hospital from 2000 to 2010 who were discharged on either torsemide or furosemide. We described baseline characteristics based on discharge diuretic and assessed the relationship with all-cause mortality through 5 years. Of 4580 patients, 86% (n = 3955) received furosemide and 14% (n = 625) received torsemide. Patients receiving torsemide were more likely to be female and had more comorbidities compared with furosemide-treated patients. Survival was worse in torsemide-treated patients [5-year Kaplan–Meier estimated survival of 41.4% (95% CI: 36.7–46.0) vs. 51.5% (95% CI: 49.8–53.1)]. After risk adjustment, torsemide use was no longer associated with increased mortality (hazard ratio 1.16; 95% CI: 0.98–1.38; P = 0.0864). Prospective trials are needed to investigate the effect of torsemide versus furosemide because of the potential for residual confounding.
    Journal of Cardiovascular Pharmacology 05/2015; 65(5):438-443. DOI:10.1097/FJC.0000000000000212 · 2.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mortality from cardiovascular diseases (CVD) represents the primary cause of death worldwide. Prevention or treatment of atherosclerosis and its clinical sequelae is a central goal in the management of patients with established vascular disease or those at high-risk for vascular events. This paper provides a review of the contemporary pharmacological armamentarium targeting atherosclerosis and also highlights strategies to support future clinical trial design. Powering future trials targeting LDL-cholesterol to its absolute reduction and including patients with a higher LDL-C despite optimal medical therapy (or unable to tolerate statins) will increase the odds of meaningful results. Mendelian randomization studies may identify new causal risk factors for CVD that would help in the selection of the patients most likely to benefit from a specific new compound. Furthermore, imaging techniques integrating a morphological and functional assessment such as IVUS, OCT, PET/CT and PET/MRI may represent in a near future robust "soft" endpoints to support successful translation of early research into meaningful phase III clinical outcome trials. Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
    International journal of cardiology 05/2015; 192. DOI:10.1016/j.ijcard.2015.05.013 · 6.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent clinical trials in patients with heart failure with preserved ejection fraction (HFpEF) have provided important insights into participant selection strategies. Historically, HFpEF trials have included patients with relatively preserved left ventricular ejection fraction ranging from 40% to 55% and a clinical history of heart failure. Contemporary HFpEF trials have also incorporated inclusion criteria such as hospitalization for HFpEF, altered functional capacity, cardiac structural and functional abnormalities, and abnormalities in neurohormonal status (e.g., elevated natriuretic peptide levels). Careful analyses of the effect of these patient selection criteria on outcomes in prior trials provide valuable lessons for future trial design. We review recent and ongoing HFpEF clinical trials from a patient selection perspective and appraise trial patient selection methodologies in relation to outcomes. This review reflects discussions between clinicians, scientists, trialists, regulators, and regulatory representatives at the 10th Global CardioVascular Clinical Trialists Forum in Paris, France, on December 6, 2013. Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
    Journal of the American College of Cardiology 04/2015; 65(16):1668-1682. DOI:10.1016/j.jacc.2015.03.043 · 15.34 Impact Factor
  • Journal of cardiac failure 04/2015; DOI:10.1016/j.cardfail.2015.04.008 · 3.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: -Although studies have shown that depression is associated with worse outcomes in heart failure (HF) patients, most studies have been in White patients. The impact of depression on outcomes in African Americans (AAs) with HF has not been studied. -We analyzed 747 AAs and 1,420 Whites enrolled in HF-ACTION, which randomized 2,331 patients with ejection fraction ≤35% to usual care with or without exercise training. We examined the association between depressive symptoms assessed by the Beck Depression Inventory II (BDI-II) at baseline and after 3 months with all-cause mortality/hospitalization. A race by baseline BDI-II interaction was observed (P=.003) in which elevated baseline scores were associated with worse outcomes in AAs versus Whites. In AAs, the association was non-linear with a hazard ratio of 1.44 (95% CI: 1.24-1.68) when comparing the 75(th) and 25(th) percentile of BDI-II (score of 15 and 5, respectively). Among Whites, the association was linear and not significant (HR 1.08, 95% CI: 0.96-1.21). No race interaction was observed for mortality (P=.34). There was no differential association between BDI-II change and outcomes in AAs vs. Whites. In AAs, an increase in BDI-II score from baseline to 3 months was associated with increased mortality/hospitalization (HR 1.33, 95% CI: 1.12-1.57 per 10 point increase), while a decrease was not related to outcomes. -In AAs with HF, baseline symptoms of depression and worsening of symptoms over time are associated with increased all-cause mortality/hospitalization. Routine assessment of depressive symptoms in AAs with HF may help guide management. Clinical Trial Registration-URL: Unique identifier: NCT00047437.
    Circulation Heart Failure 04/2015; DOI:10.1161/CIRCHEARTFAILURE.114.001995 · 5.95 Impact Factor
  • American Heart Journal 04/2015; DOI:10.1016/j.ahj.2015.04.007 · 4.56 Impact Factor
  • Journal of the American College of Cardiology 03/2015; 65(10):A815. DOI:10.1016/S0735-1097(15)60815-4 · 15.34 Impact Factor
  • Lauren B Cooper · Robert J Mentz
    Chest 03/2015; 147(3):586-8. DOI:10.1378/chest.14-2081 · 7.13 Impact Factor
  • Journal of the American College of Cardiology 03/2015; 65(10):A1034. DOI:10.1016/S0735-1097(15)61034-8 · 15.34 Impact Factor

Publication Stats

462 Citations
681.85 Total Impact Points


  • 2015
    • North Carolina Clinical Research
      Raleigh, North Carolina, United States
  • 2012–2015
    • Duke University
      • Department of Medicine
      Durham, North Carolina, United States
  • 2011–2015
    • Duke University Medical Center
      • • Division of Cardiology
      • • Duke Clinical Research Institute
      Durham, North Carolina, United States
    • Brigham and Women's Hospital
      • Department of Medicine
      Boston, Massachusetts, United States
  • 2014
    • Aalborg University
      Ålborg, North Denmark, Denmark
  • 2013
    • Durham University
      Durham, England, United Kingdom